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Endotracheal Involvement as an Unusual 
Extranodal Site of Recurrence from Mantle 
Cell Lymphoma 
Franco Verde, M.D., and Ann McGeehan, M.D.
Mantle cell lymphomas are uncommon subtypes of non-Hodgkin’s lymphoma with poor over-
all survival ranging from 3-5 years. Patients are often middle aged men who would present with 
generalized lymphadenopathy and typical constitutional symptoms. Extranodal disease is typically 
found in the gastrointestinal tract, liver, spleen, and central nervous system. Lung involvement is 
typically restricted to parenchymal lesions. Endotracheal involvement is quite uncommon with 
less than 5% of cases. We present an unusual case of treated mantle cell lymphoma recurring 7 
years later with only endotracheal involvement demonstrated by fluorodeoxyglucose-positron 
emission tomography.
Mantle cell lymphomas are uncommon subtypes of 
non-Hodgkin’s lymphoma with poor overall survival 
ranging from 3-5 years. Patients are often middle aged 
men who would present with generalized lymphadenop-
Introduction
Figure 1. 55-year-old man with recurrent mantle cell lym-
phoma. CT shows symmetric circumferential thickening of 
the distal trachea (arrows).
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Figure 2. Axial PET/CT shows intense activity in the suspected area around the distal 
trachea.
In 2004, more than 56,000 cases of non-Hodgkin’s 
lymphoma occurred in the United States with an inci-
dence of about 22 per 100,000 and a death rate of about 
8.8 per 100,000. Mantle cell lymphomas represent 
Discussion
A 55-year-old man presented to the emergency room 
complaining of left lower quadrant abdominal pain, 
abdominal distention and nausea. Review of systems 
revealed a 20-pound weight loss over four months and 
frequent night sweats. No prior history of malignancy. 
His mother died of Hodgkin’s lymphoma. Patient has a 
history of coronary artery disease status post angioplasty, 
hypercholesterolemia, and hypertension. Physical exam 
revealed a markedly enlarged tender spleen and inguinal 
lymphadenopathy. Lab work revealed anemia, leuko-
cytosis and borderline thrombocytopenia. CT scan was 
performed which demonstrated splenomegaly. Lymph 
Case Report
athy and typical constitutional symptoms. Extranodal 
disease is typically found in the gastrointestinal tract, 
liver, spleen, and central nervous system. Lung involve-
ment is typically restricted to parenchymal lesions. 
Endotracheal involvement is quite uncommon with less 
than 5% of cases. We present an unusual case of treated 
mantle cell lymphoma recurring 7 years later with only 
endotracheal involvement demonstrated by fluorodeoxy-
glucose-positron emission tomography.
node and bone marrow biopsy was performed which 
revealed non-Hodgkin’s lymphoma, mantle-cell type.
Patient was then started on chemotherapy us-
ing the CHOP protocol for six cycles. Rituxan was 
added 6 months later after a partial response. Patient 
later received an autologous stem cell transplant in 
March 2001. Patient also underwent splenectomy after 
transplant. Patient remained in remission until fol-
low up CAT scan performed in January 2008 which 
demonstrated circumferential thickening of the distal 
trachea (Figure 1). 18F-FDG PET scan was performed a 
month later demonstrating avidity only within the distal 
trachea (Figures 2 and 3). Bronchoscopy and biopsy was 
performed which was positive for mantle cell lym-
phoma. Patient refused surgery and was then referred to 
radiation oncology for up to 4000 cGy delivered to the 
distal trachea. 
between 4-8 percent of 
non-Hodgkin’s lymphomas. 
Older individuals are more 
affected with the median age 
of diagnosis of 63 years. The 
male to female ratio is about 
4 to 1 [1, 2].
Diagnosis primar-
ily rests upon biopsy of an 
affected lymph node or 
extranodal site of disease. 
Specific classification relies 
upon the specific macro and 
microscopic appearance in 
addition to its immunologi-
cal phenotype and genetic 
abnormalities. CD markers 
include: CD20+, CD3-, 
CD10-, CD5+, CD24-, and 
PRADI+. The most frequent 
cytogenetic abnormal-
ity would include t(11;14)
(q13;q32). Mantle cell lym-
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Figure 3. Full body coronal reformatted PET scan shows ab-
normal intense tracheal uptake and other areas of expected 
uptake.
phomas are associated with the bcl-1 oncogene [1].
Mantle cell lymphomas are frequently diagnosed, 
over 70% of the time, with stage IV disease involving 
more than one extranodal site in 50% of cases. Clini-
cally, again generally being older men, will present with 
generalized lymphadenopathy, sometimes massive sple-
nomegaly and diffuse GI polypoid lesions in addition to 
the typical “B” symptoms [1]. Mantle cell lymphomas 
are considered to be an indolent lymphoma variant 
with patients surviving many years without treatment. 
Aggressive disease will usually get a standard CHOP-R 
regimen. Patients will usually experience a very high 
overall response rate to induction treatment with a short 
time to progression. Overall survival is about 3-4 years 
[1].
Extranodal sites of non-Hodgkin’s lymphomas com-
monly involve the gastrointestinal tract, liver, spleen, 
central nervous system, bone marrow, pulmonary 
parenchyma and pleura. Other sites account for less 
than 5-10% such as kidneys, adrenals, testes, bone, head 
and neck. Rarely will muscle, breast, pancreas, and the 
trachea be involved [3].
CT has been the gold standard for staging, how-
ever is limited to only structural detail. Extranodal 
spread can be missed if not pathologic by appearance. 
For initial staging, studies have shown that upstaging 
occurs in about 20% of patients when 18F-FDG PET 
is added. Aggressive disease can also be determined by 
SUV uptake greater than 10. PET will also add informa-
tion about treatment response and prognosis. Combined 
PET/CT can increase sensitivity and decrease false posi-
tives partially when brown adipose tissue mimics disease 
[4].
Our patient’s CT at interval follow-up, prompted 
addition of PET to confirm disease versus other benign 
entities (e.g. endotracheal mucus). CT alone could have 
delayed treatment. For the time interval and site of 
recurrence, this case is quite unusual. 
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